PubRank

Fergus J Couch

Author PubWeight™ 315.05‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007 29.23
2 Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010 8.93
3 Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013 8.24
4 A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007 7.35
5 Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006 7.33
6 Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005 6.90
7 Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010 6.04
8 Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008 5.98
9 A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 2007 5.17
10 Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014 4.97
11 A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 2010 4.96
12 Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 2015 4.77
13 Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 2004 4.61
14 Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2010 4.54
15 The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2006 4.35
16 Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013 4.35
17 Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 2009 4.13
18 Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 2013 3.81
19 RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 2007 3.63
20 Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008 3.41
21 A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet 2011 3.37
22 Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 2012 3.20
23 Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 2007 3.11
24 Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst 2009 2.88
25 Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet 2011 2.72
26 An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res 2007 2.46
27 A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet 2012 2.45
28 A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 2006 2.27
29 Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet 2013 2.24
30 Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 2005 2.16
31 Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2009 2.13
32 The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res 2011 2.09
33 Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 2009 2.04
34 Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2011 1.99
35 ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat 2011 1.94
36 Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2007 1.92
37 Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 2010 1.90
38 A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat 2011 1.90
39 Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res 2007 1.89
40 Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet 2013 1.88
41 19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res 2012 1.81
42 Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 2008 1.79
43 Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet 2011 1.77
44 Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet 2010 1.74
45 Prediction and assessment of splicing alterations: implications for clinical testing. Hum Mutat 2008 1.73
46 Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology 2011 1.70
47 Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer. J Natl Cancer Inst 2014 1.66
48 Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res 2011 1.65
49 Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells. Cancer Biol Ther 2006 1.62
50 Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Res 2007 1.61
51 Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet 2009 1.58
52 Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol 2008 1.56
53 Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet 2010 1.56
54 Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet 2013 1.56
55 Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Res 2010 1.51
56 Genetic susceptibility to triple-negative breast cancer. Cancer Res 2013 1.48
57 A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene 2004 1.47
58 Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2010 1.41
59 The 17q23 amplicon and breast cancer. Breast Cancer Res Treat 2003 1.40
60 Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2008 1.39
61 Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet 2013 1.39
62 Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res 2012 1.38
63 Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun 2013 1.36
64 Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology 2013 1.34
65 A guide for functional analysis of BRCA1 variants of uncertain significance. Hum Mutat 2012 1.34
66 The role of Tbx2 and Tbx3 in mammary development and tumorigenesis. J Mammary Gland Biol Neoplasia 2004 1.31
67 Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage. J Biol Chem 2005 1.31
68 Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs. Hum Mutat 2011 1.31
69 Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2009 1.29
70 CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol 2012 1.29
71 Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis 2013 1.28
72 A novel automated mammographic density measure and breast cancer risk. J Natl Cancer Inst 2012 1.28
73 11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat 2012 1.26
74 Strong evidence of a genetic determinant for mammographic density, a major risk factor for breast cancer. Cancer Res 2007 1.26
75 Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk. Cancer Epidemiol Biomarkers Prev 2012 1.26
76 Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov 2012 1.25
77 A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches. Breast Cancer Res Treat 2006 1.25
78 Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A 2002 1.23
79 Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol Biomarkers Prev 2011 1.23
80 The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet 2012 1.23
81 Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res 2011 1.22
82 A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. Cancer Res 2012 1.21
83 Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 2005 1.18
84 On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 2010 1.17
85 TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. Cancer Res 2002 1.17
86 Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. J Natl Cancer Inst 2010 1.17
87 Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2010 1.15
88 A computational method to classify variants of uncertain significance using functional assay data with application to BRCA1. Cancer Epidemiol Biomarkers Prev 2011 1.15
89 Functional assays for BRCA1 and BRCA2. Int J Biochem Cell Biol 2006 1.15
90 BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management. Oncologist 2013 1.15
91 Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev 2011 1.14
92 Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS One 2012 1.13
93 Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. Hum Mutat 2010 1.13
94 BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. J Med Genet 2012 1.13
95 Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol 2011 1.12
96 The influence of mammogram acquisition on the mammographic density and breast cancer association in the Mayo Mammography Health Study cohort. Breast Cancer Res 2012 1.11
97 Automated discovery of drug treatment patterns for endocrine therapy of breast cancer within an electronic medical record. J Am Med Inform Assoc 2011 1.09
98 BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol 2002 1.06
99 Identification of inherited genetic variations influencing prognosis in early-onset breast cancer. Cancer Res 2013 1.06
100 Microcephalin regulates BRCA2 and Rad51-associated DNA double-strand break repair. Cancer Res 2009 1.06
101 Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res 2011 1.05
102 Genetic variation in the chromosome 17q23 amplicon and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2009 1.05
103 Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies. Breast Cancer Res 2008 1.04
104 Mammographic breast density and breast cancer: evidence of a shared genetic basis. Cancer Res 2012 1.03
105 Association of genetic variation in mitotic kinases with breast cancer risk. Breast Cancer Res Treat 2009 1.02
106 BRCA2 localization to the midbody by filamin A regulates cep55 signaling and completion of cytokinesis. Dev Cell 2012 1.02
107 Cancer risk assessment at the atomic level. Cancer Res 2006 1.01
108 Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2010 1.01
109 A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. Hum Mol Genet 2013 1.00
110 Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary. Hum Mutat 2011 1.00
111 Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res 2014 0.99
112 Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Cancer Res 2008 0.98
113 Allele-specific expression in the germline of patients with familial pancreatic cancer: an unbiased approach to cancer gene discovery. Cancer Biol Ther 2007 0.98
114 Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat 2012 0.98
115 BRCA2 and pancreatic cancer. Int J Gastrointest Cancer 2002 0.98
116 p53 mediates repression of the BRCA2 promoter and down-regulation of BRCA2 mRNA and protein levels in response to DNA damage. J Biol Chem 2003 0.97
117 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2012 0.95
118 Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer 2012 0.95
119 Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res 2008 0.95
120 Rare variants in XRCC2 as breast cancer susceptibility alleles. J Med Genet 2012 0.94
121 No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer. BMC Cancer 2009 0.93
122 Dual recognition of phosphoserine and phosphotyrosine in histone variant H2A.X by DNA damage response protein MCPH1. Proc Natl Acad Sci U S A 2012 0.93
123 Functional assays for analysis of variants of uncertain significance in BRCA2. Hum Mutat 2013 0.92
124 Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. Cancer Epidemiol Biomarkers Prev 2010 0.91
125 Tex14, a Plk1-regulated protein, is required for kinetochore-microtubule attachment and regulation of the spindle assembly checkpoint. Mol Cell 2012 0.91
126 Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers. Cancer Res 2008 0.91
127 Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol 2012 0.91
128 Evaluation of associations between common variation in mitotic regulatory pathways and risk of overall and high grade breast cancer. Breast Cancer Res Treat 2011 0.90
129 Risk of ovarian cancer and inherited variants in relapse-associated genes. PLoS One 2010 0.90
130 COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. Breast Cancer Res 2013 0.90
131 BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst 2015 0.90
132 No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. Breast Cancer Res Treat 2008 0.90
133 Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Hum Genet 2014 0.89
134 Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2014 0.89
135 Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Hum Mol Genet 2011 0.89
136 A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012 0.89
137 Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. Breast Cancer Res 2012 0.88
138 DNA mismatch repair gene MSH6 implicated in determining age at natural menopause. Hum Mol Genet 2013 0.88
139 Poly(ADP-ribose) polymerase-1 down-regulates BRCA2 expression through the BRCA2 promoter. J Biol Chem 2008 0.88
140 Identification of a novel percent mammographic density locus at 12q24. Hum Mol Genet 2012 0.88
141 Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas. Mod Pathol 2004 0.87
142 Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet 2011 0.87
143 Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer. Twin Res Hum Genet 2010 0.87
144 Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer. Breast Cancer Res 2010 0.87
145 Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk. Cancer Res 2006 0.86
146 ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer. BMC Cancer 2014 0.84
147 No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Res Treat 2008 0.84
148 Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2011 0.83
149 Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study. Endocr Relat Cancer 2013 0.83
150 CYP2B6*6 is associated with increased breast cancer risk. Int J Cancer 2013 0.82
151 Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res 2010 0.82
152 Molecular basis for the association of microcephalin (MCPH1) protein with the cell division cycle protein 27 (Cdc27) subunit of the anaphase-promoting complex. J Biol Chem 2011 0.81
153 Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2014 0.81
154 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. J Med Genet 2011 0.80
155 Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS One 2012 0.80
156 Common variation in Nemo-like kinase is associated with risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2012 0.80
157 The germline MLH1 K618A variant and susceptibility to Lynch syndrome-associated tumors. J Mol Diagn 2012 0.79
158 Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. Breast Cancer Res 2015 0.79
159 Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Res 2011 0.79
160 Von Hippel-Lindau gene product directs cytokinesis: a new tumor suppressor function. J Cell Sci 2011 0.79
161 Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes. Brief Bioinform 2015 0.78
162 Polymorphic variants in hereditary pancreatic cancer genes are not associated with pancreatic cancer risk. Cancer Epidemiol Biomarkers Prev 2009 0.78
163 A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. Breast Cancer Res Treat 2015 0.78
164 Mutation screening of RAD51C in high-risk breast and ovarian cancer families. Fam Cancer 2012 0.78
165 Spontaneous vulvar papillomas in a colony of mice used for pancreatic cancer research. Comp Med 2008 0.78
166 Gene-expression-based predictors for breast cancer. N Engl J Med 2007 0.77
167 The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant. Breast Cancer Res Treat 2011 0.76
168 Targeted Therapy for BRCA2 Deficient Tumors. Cancer Biol Ther 2005 0.76
169 Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst 2017 0.75
170 No evidence for association of inherited variation in genes involved in mitosis and percent mammographic density. Breast Cancer Res 2012 0.75
171 Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Res Treat 2012 0.75
172 Linkage analysis of obesity phenotypes in pre- and post-menopausal women from a United States mid-western population. BMC Med Genet 2010 0.75
173 Corrigendum: Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nat Commun 2015 0.75